ArticleThoracic cancer2023

Investigation of response factors for monotherapy with immune checkpoint inhibitors in non-small cell lung cancer patients with PD-L1 expression <50.

Yutaka Takahara et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.